Phenotypic and functional characteristics of tumor-associated lymphocytes in patients with malignant ascites receiving intraperitoneal infusions of recombinant interleukin-2 (rIL-2). 1989

G Melioli, and E Baldini, and M C Mingari, and A De Maria, and M R Sertoli, and F Badellino, and P L Percivale, and A Catturich, and S Bertoglio, and D Civălleri
Laboratorio di Immunopatologia, Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy.

In the course of a phase I trial, in which recombinant IL-2 (rIL-2) was infused intraperitoneally (i.p.) in patients with peritoneal carcinomatosis, we evaluated the effect on "tumor-associated lymphocytes" (TAL) isolated from the ascitic fluid. No major changes in the percentages of cells expressing the CD3, CD4, CD8, Leu-7, OKM1 and WT-31 antigens were detected either in TAL or in peripheral blood lymphocytes (PBL) after 7 days of rIL-2 infusion. In contrast the percentages of TAL (but not PBL) expressing surface IL-2 receptor (Tac), or LAK-1 antigen were sharply increased. Analysis of cytolytic functions showed a potentiation of the lytic activity against natural-killer (NK) sensitive K562 target cells and the de novo appearance of lytic activity against fresh melanoma cells. In one patient IFN-gamma was detected in the ascitic fluid following rIL-2 infusion. T-cell clones derived from the patient were analyzed for the IFN-gamma production. While only approximately 40% of PB-derived control clones produced medium to low amounts of IFN-gamma, all of the TAL-derived clones produced medium to high amounts of the lymphokine.

UI MeSH Term Description Entries
D007263 Infusions, Parenteral The administration of liquid medication, nutrient, or other fluid through some other route than the alimentary canal, usually over minutes or hours, either by gravity flow or often by infusion pumping. Intra-Abdominal Infusions,Intraperitoneal Infusions,Parenteral Infusions,Peritoneal Infusions,Infusion, Intra-Abdominal,Infusion, Intraperitoneal,Infusion, Parenteral,Infusion, Peritoneal,Infusions, Intra-Abdominal,Infusions, Intraperitoneal,Infusions, Peritoneal,Intra Abdominal Infusions,Intra-Abdominal Infusion,Intraperitoneal Infusion,Parenteral Infusion,Peritoneal Infusion
D007371 Interferon-gamma The major interferon produced by mitogenically or antigenically stimulated LYMPHOCYTES. It is structurally different from TYPE I INTERFERON and its major activity is immunoregulation. It has been implicated in the expression of CLASS II HISTOCOMPATIBILITY ANTIGENS in cells that do not normally produce them, leading to AUTOIMMUNE DISEASES. Interferon Type II,Interferon, Immune,gamma-Interferon,Interferon, gamma,Type II Interferon,Immune Interferon,Interferon, Type II
D007376 Interleukin-2 A soluble substance elaborated by antigen- or mitogen-stimulated T-LYMPHOCYTES which induces DNA synthesis in naive lymphocytes. IL-2,Lymphocyte Mitogenic Factor,T-Cell Growth Factor,TCGF,IL2,Interleukin II,Interleukine 2,RU 49637,RU-49637,Ro-23-6019,Ro-236019,T-Cell Stimulating Factor,Thymocyte Stimulating Factor,Interleukin 2,Mitogenic Factor, Lymphocyte,RU49637,Ro 23 6019,Ro 236019,Ro236019,T Cell Growth Factor,T Cell Stimulating Factor
D007694 Killer Cells, Natural Bone marrow-derived lymphocytes that possess cytotoxic properties, classically directed against transformed and virus-infected cells. Unlike T CELLS; and B CELLS; NK CELLS are not antigen specific. The cytotoxicity of natural killer cells is determined by the collective signaling of an array of inhibitory and stimulatory CELL SURFACE RECEPTORS. A subset of T-LYMPHOCYTES referred to as NATURAL KILLER T CELLS shares some of the properties of this cell type. NK Cells,Natural Killer Cells,Cell, NK,Cell, Natural Killer,Cells, NK,Cells, Natural Killer,Killer Cell, Natural,NK Cell,Natural Killer Cell
D008214 Lymphocytes White blood cells formed in the body's lymphoid tissue. The nucleus is round or ovoid with coarse, irregularly clumped chromatin while the cytoplasm is typically pale blue with azurophilic (if any) granules. Most lymphocytes can be classified as either T or B (with subpopulations of each), or NATURAL KILLER CELLS. Lymphoid Cells,Cell, Lymphoid,Cells, Lymphoid,Lymphocyte,Lymphoid Cell
D010641 Phenotype The outward appearance of the individual. It is the product of interactions between genes, and between the GENOTYPE and the environment. Phenotypes
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001201 Ascites Accumulation or retention of free fluid within the peritoneal cavity.
D015375 Receptors, Interleukin-2 Receptors present on activated T-LYMPHOCYTES and B-LYMPHOCYTES that are specific for INTERLEUKIN-2 and play an important role in LYMPHOCYTE ACTIVATION. They are heterotrimeric proteins consisting of the INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT, the INTERLEUKIN-2 RECEPTOR BETA SUBUNIT, and the INTERLEUKIN RECEPTOR COMMON GAMMA-CHAIN. IL-2 Receptors,Interleukin-2 Receptor,Interleukin-2 Receptors,Receptors, IL-2,Receptors, T-Cell Growth Factor,T-Cell Growth Factor Receptors,IL-2 Receptor,IL2 Receptor,IL2 Receptors,Interleukin 2 Receptor,Receptor, TCGF,T-Cell Growth Factor Receptor,TCGF Receptor,TCGF Receptors,IL 2 Receptor,IL 2 Receptors,Interleukin 2 Receptors,Receptor, IL-2,Receptor, IL2,Receptor, Interleukin 2,Receptor, Interleukin-2,Receptors, IL 2,Receptors, IL2,Receptors, Interleukin 2,Receptors, T Cell Growth Factor,Receptors, TCGF,T Cell Growth Factor Receptor,T Cell Growth Factor Receptors

Related Publications

G Melioli, and E Baldini, and M C Mingari, and A De Maria, and M R Sertoli, and F Badellino, and P L Percivale, and A Catturich, and S Bertoglio, and D Civălleri
August 1993, Nihon Geka Gakkai zasshi,
G Melioli, and E Baldini, and M C Mingari, and A De Maria, and M R Sertoli, and F Badellino, and P L Percivale, and A Catturich, and S Bertoglio, and D Civălleri
February 1990, Gastroenterology,
G Melioli, and E Baldini, and M C Mingari, and A De Maria, and M R Sertoli, and F Badellino, and P L Percivale, and A Catturich, and S Bertoglio, and D Civălleri
August 1989, Journal of biological response modifiers,
G Melioli, and E Baldini, and M C Mingari, and A De Maria, and M R Sertoli, and F Badellino, and P L Percivale, and A Catturich, and S Bertoglio, and D Civălleri
March 1990, British journal of cancer,
G Melioli, and E Baldini, and M C Mingari, and A De Maria, and M R Sertoli, and F Badellino, and P L Percivale, and A Catturich, and S Bertoglio, and D Civălleri
January 1990, Biotherapy (Dordrecht, Netherlands),
G Melioli, and E Baldini, and M C Mingari, and A De Maria, and M R Sertoli, and F Badellino, and P L Percivale, and A Catturich, and S Bertoglio, and D Civălleri
April 1994, British journal of haematology,
G Melioli, and E Baldini, and M C Mingari, and A De Maria, and M R Sertoli, and F Badellino, and P L Percivale, and A Catturich, and S Bertoglio, and D Civălleri
June 1990, Nihon Hinyokika Gakkai zasshi. The japanese journal of urology,
G Melioli, and E Baldini, and M C Mingari, and A De Maria, and M R Sertoli, and F Badellino, and P L Percivale, and A Catturich, and S Bertoglio, and D Civălleri
January 1993, Surgery today,
G Melioli, and E Baldini, and M C Mingari, and A De Maria, and M R Sertoli, and F Badellino, and P L Percivale, and A Catturich, and S Bertoglio, and D Civălleri
April 1994, Melanoma research,
G Melioli, and E Baldini, and M C Mingari, and A De Maria, and M R Sertoli, and F Badellino, and P L Percivale, and A Catturich, and S Bertoglio, and D Civălleri
January 1993, Biotherapy (Dordrecht, Netherlands),
Copied contents to your clipboard!